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ABSTRACT
Objectives: Human Epididymal Secretory Protein 4 was firstly described as an epididymis-specific protein but more recently 
it has been demonstrated to be a putative serum tumor marker for different malignancies, especially ovarian epithelial 
cancers. The aim of this study is to investigate the association between tissue Human Epididymal Secretory Protein 4 ex-
pression and the clinicopathological features of uterine cervical tumors.
Material and methods: This retrospective study was designed to evaluate the differences of tissue expressions of Hu-
man Epididymal Secretory Protein 4 protein in a spectrum of cervical neoplasms. One hundred and seven patients recently 
diagnosed as having cervical intraepithelial neoplasm or invasive squamous cell carcinoma, adenosquamous carcinoma 
and adenocarcinoma based on pathology databases. 
Results: Decreased or negative Human Epididymal Secretory Protein 4 expressions were determined in both normal cervical 
epithelia and in intraepithelial carcinomas, while increased HE4 expression was observed in invasive tumors.
Conclusions: This study demonstrated that altered expression of Human Epididymal Secretory Protein 4 may involve in 
tumorigenesis in the uterine cervix. Our findings also suggested the presence of a correlation between Human Epididymal 
Secretory Protein 4 expression and the invasive potential of uterine tumors. Therefore it may be thought that the tissue 
expression of HE4 can be used to differentiate high grade intraepithelial tumors from carcinomas. 
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INTRODUCTION
Human Epididymal Secretory Protein 4 (HE4) was discov-
ered by Kirchhoff et al. [1] in 1991. HE4 contains four disulfide 
core proteins and due to similarities with other whey acidic 
protein family members, it functions as a proteinase inhibi-
tor [2, 3]. Firstly, presence of HE4 in the distal regions of the 
epithelial cells of the epididymal duct, suggests its roles in 
sperm maturation [1–5]. Currently, it is known that HE4 is 
expressed in a large spectrum of normal and malignant tis-
sues. Majority of secretory cells such as glandular epithelium 
of the breast and female genital tract, epididymis, vas defer-
ens, distal renal tubules, respiratory epithelium and salivary 
glands show strong HE4 positivity [6]. Physiopathologically, 
HE4 probably involves in cancer progression and metastases 
[7]. In intact tissues of trachea and salivary gland highest 
levels of HE4 expression, while in lung, prostate, pituitary 
gland, thyroid and kidney lower HE4 positivity have been de-
tected. Some studies have shown marked HE4 expressions 
in ovarian epithelial cancers, mesotheliomas, transitional 
cell carcinomas and tumors of lung, endometrium, breast, 
gastrointestinal system and kidney [6]. Ovarian epithelial 
cancers, especially serous and endometrioid ovarian cancers 
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have demonstrated highest rates of HE4 positivity among 
these tumors [8].
In spite of frequent implementation of screening pro-
grams, uterine cervical cancers are still one of the main 
causes of cancer mortality among female population around 
the world [9, 10]. Squamous cell carcinoma (SCC) is the most 
frequent histological type accounting for 75–80% of inva-
sive uterine cervical carcinomas [9–11]. Adenosquamous 
carcinomas (ASCs) can be defined as tumors that contain 
a mixture of malign squamous and glandular cells. ASC is 
the second frequent cervical cancer and its incidence is 
reported to range between 3.6 % and 25% among all cer-
vical cancers. The prevalence of ASC is higher particularly 
in young women. It metastasizes to pelvic lymph nodes 
twice as frequently as SCC or adenocarcinomas [8–10]. Most 
authors have reported a poorer prognosis for patients with 
ASCs. Other type is pure adenocarcinoma (AC) of the uterine 
cervix. Squamous and glandular components of cervical 
cancers are monoclonal in origin and arise from the pluripo-
tent subcolumnar reserve cells of the endocervical mucous 
epithelium [8–11].
In the past decade, HE4 emerged as a promising bio-
marker to address the unmet clinical needs in ovarian and 
endometrial cancer. Herein, we studied the immune expres-
sions of HE4 in different uterine cervical malignancies. In 
addition, we aimed to determine both the role of HE4 in 
the differential diagnosis among uterine cervical tumors, 
and its prognostic value.
MATERIAL AND METHODS
At Tepecik Training and Research Hospital 107 patients 
with the diagnoses of CIN, SCC, ASC and AC based on im-
munohistochemical analysis of pathology specimens were 
included in the study. The study was approved by the Local 
Ethics Committee of the Hospital. 
For immunhistochemistry (IHC), hematoxylin and eosin 
(HE) staining was used to select appropriate paraffin blocks 
and to identify the viable tumor areas. For the assessment 
of HE4 expression in normal cervical epithelium, we also se-
lected specific paraffin blocks which contained both tumor 
areas and surrounding normal tissues. IHC was performed 
using streptavidine biotin peroxidase method (Invitrogen, 
Camarillo, 85–9043, CA, USA). Serial 5-µm-thick sections 
were obtained and these slides were baked overnight at 
600C, dewaxed in xylene, hydrated with distilled water, then 
treated with decreasing concentrations of alcohol. All slides 
were subjected to heat- induced epitope retrieval proce-
dure in the microwave (in 10 mM/L citrate buffer, pH 6.0, 
for 20 minutes, followed by cooling at room temperature 
for 20 minutes) so as to block endogenous peroxidase and 
biotin activities. The purified monoclonal mouse antibodies 
against Human Epididymal protein 4 (Anti-HE4 Ab, Abcam, 
ab24480) were used at a dilution of 1:40. Laboratory tests 
were evaluated by a researchers (GD, SS, DA) blinded to 
the clinical features of the patients. Strong and diffuse cy-
toplasmic staining indicated presence of HE4 expression. 
Chi-square test was performed for statistical analysis using 
SPSS 15.0. software statistical package program. P values 
less than 0.05 were considered to be statistically significant. 
RESULTS
This series consisted of 30 (28%) low (CIN1), 29 (27.1%) 
high grade CINs (CIN2 and CIN3), 27 (25.2%) SCCs, 
15 (14%) ASCs and 6 (5.6%) ACs. Mean age of the patients 
was 47.9 ± 12.8 years (ranging from 20 to 80 years). The 
cases with invasive carcinomas (52.6 ± 13.2 years/30 to 
80 years) were older than cases with intraepithelial neo-
plasms (44.01 ± 11.1 years/20 to 66 years). Contrarily, the 
mean age was similar in all invasive tumor groups. For ex-
ample the mean age for SCC was 52.8 ± 14.8, while it was 
52.9 ± 12.1 and 51.5 ± 9.2 for ASC and AC, respectively. 
Decreased or negative HE4 expressions were detected 
both in normal cervical epithelia and in most intraepithelial 
carcinomas (Fig. 1). HE4 expression was determined in 45 of 
48 invasive carcinomas (93.8%), and in only 34 of 59 noninva-
sive neoplasms (57.6%) Fisher’s Exact Test, revealed a statisti-
cally significant correlation between cellular invasion and 
HE4 expression (p < 0.001) (Fig. 2). Conversely, there was 
no association between subtypes of invasive tumors and 
expressions of HE4 (p = 0.595) (Fig. 3).
DISCUSSION
HE4 is a novel biomarker that is expressed in most of the 
epithelial ovarian cancers but not in normal surface epithe-
lium [12]. HE4 is expressed in the Mullerian type epithelium 
of ovarian cortical inclusion cysts which suggested that 
HE4 might be a significant predictor for Mullerian- derived 
tumors [13]. A prominent upregulation of HE4 immune ex-
pression has been seen in female genital cancers, especially 
in ovarian serous and endometrioid carcinomas. Detection 
of HE4 expression with immunohistochemical staining in 
several studies has revealed that HE4 is expressed in all 
endometrioid adenocarcinomas, 90% of serous adenocar-
cinomas and 50% of clear cell epithelial ovarian cancers [12, 
13]. Interestingly, high HE4 tissue expression is mostly found 
in epithelial ovarian adenocarcinomas [13]. Conversely, 
HE4 overexpression has not been detected in ovarian mu-
cinous tumors [4–6], non-epithelial ovarian cancers, sex 
cord stromal tumors and germ cell tumors. However over-
expression of HE4 has been detected in primary tuba uterina 
carcinomas and endometrial malignancies [2–7]. Among 
non-gynecological cancers, HE4 expression has been also 
demonstrated in various subtypes of lung cancer [12]. The 
lowest HE4 expression has been detected in small-cell car-
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cinomas when compared with non-small cell carcinomas 
such as squamous cell carcinomas, adenocarcinomas and 
large-cell lung cancers [4, 14–16]. In the gastrointestinal 
system, HE4 tissue overexpression was found in stomach 
[18], pancreatic, colorectal , and hepatocellular carcinomas 
[4, 14, 18, 19]. In the urological tract, varying HE4 expres-
sion levels were showed in clear cell carcinomas, papillary 
renal cell carcinomas, and chromophobe carcinomas [4, 
12, 18–20]. Although HE4 expression has been extensively 
studied in several carcinomas, there are little or no data on 
the expression and significance of HE4 in the uterine cervical 
tumors. In this study, majority of uterine cervical carcinomas 
demonstrated HE4 expression without any statistical signifi-
cant difference among subtypes of carcinomas. 
Currently HE4 levels have been measured both in tissue 
sections, and sera. The potential use of HE4 as a tumor mark-
er has been supported by an increasing number of studies 
demonstrating an upregulation of HE4 in a range of malig-
nant neoplasms, particularly of gynecological, pulmonary 
and gastrointestinal origin [3, 12, 13, 16, 17, 21]. Serological 
tests have revealed that HE4 has increased sensitivity and 
specificity in the detection of ovarian cancer relative to CA 
125, which is the current gold standard serum biomarker 
for ovarian carcinomas [3, 12]. Several studies examining 
multiple serum biomarkers for epithelial ovarian carcinomas 
have found the combination of HE4 and CA125 had greater 
sensitivity and specificity than either marker alone. Because 
CA 125 is often elevated in benign conditions or as a result 
of physiologic changes in premenopausal women, it has 
not any confirmed role in the early detection of gyneco-
logic cancers. Since abnormal levels of HE4 have been less 
frequently encountered in benign gynecological conditions 
HE4 may have increased specificity in differentiating be-
tween benign and malignant conditions [2–7]. In the present 
study, we have found that HE4 tissue expression increased 
in carcinomas, but decreased in intraepithelial neoplasia. We 
thought that the screening test for serum HE4 level may be 
also clinically useful in the differential diagnosis between 
Figure 1 A. Note HE4 positivity in invasive component of a SCC and tHE4 negativity in normal cervical epithelium on the left of field, B. strong HE4 
expression in an adenosquamous carcinoma, and C. weak HE4 expression in an adenocarcinoma (DABX 100)
Figure 2. Higher HE4 expression in invasive carcinomas, relative to 
lower HE expression in intraepithelial tumors (p < 0.001)
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invasive and intraepithelial cervical neoplasms. Despite the 
fact that our data require further evaluation on a large scale 
population, it can be suggested that the tissue expression of 
HE4 can be used to differentiate the CIN from carcinomas. 
In this study, the higher HE4 expression was found 
mainly in invasive carcinomas of the uterine cervix com-
pared to non-invasive carcinomas. The relationship between 
uterine cervical neoplasms and HE4 expression has not been 
investigated in the literature up to now. However similar 
results were reported about ovarian epithelial neoplasms 
[14, 20]. For example Georgakopoulos et al. [14] determined 
that HE4 protein was significantly upregulated in epithelial 
carcinomas compared with benign or borderline tumors. In 
this study, we compared HE4 immune expression levels 
in several subtypes of cervical uterine tumors and found 
significant differences in HE4 expression levels between 
invasive carcinomas and CINs. Since comparative studies 
on this issue has not been cited in the literature we haven’t 
enough data to discuss HE4 immune expression levels in 
uterine cancer subtypes. 
Guo et al. [21] reported that HE4 was significantly up-
regulated in human gastric cancer and correlated with 
some prognostic factors such as TNM stage, tumor size, 
and survival. The overall survival rate of patients without 
HE4 expression was significantly higher than those with 
HE4 overexpression. In addition, the authors demonstrated 
that silencing HE4 expression inhibited celluar proliferation, 
migration and enhanced apoptosis. They also suggested 
that HE4 might regulate proliferation, migration, and ap-
optosis through Src/Fak, Akt, and Erk1/2 signaling in gastric 
cancer cells [21]. For these reasons, HE4 may not be only 
a useful diagnostic marker, but also it might have thera-
peutic implications for several cancer types [21]. To the 
best of our knowledge, the present study was the first to 
determine the differential diagnostic value of HE4 tissue 
expression for uterine cervical cancers. Unfortunately it 
has certain limitations. Its most evident limitation was its 
small sample size. In future studies, it may be appropriate 
to compare expression levels HE4 in tissue samples , and 
sera in patients with carcinoma in situ and invasive tumors 
of uterine cervix. The observations of the present study 
should be confirmed by future studies using a larger cohort 
and additional serum analyses. 
Herein, we compared HE4 expression patterns in both 
non-invasive and invasive cervical neoplasms. HE4 protein 
was significantly upregulated in different subtypes of in-
vasive cervical neoplasms compared with intra-epithelial 
neoplasms. In addition, we have demonstrated for the first 
time, that high HE4 expression correlates with an aggressive 
phenotype and may constitute an independent prognostic 
factor for uterine cervical neoplasms. In conclusion, the 
altered expression of HE4 may play a role in tumorigenesis 
in most SCCs, ASCAs and ACs of uterine cervix. Therefore 
HE4 expression may be important for the prediction of 
the tumor progression. In ddition, determination of serum 
HE4 could be clinically useful in identifying high-risk patients 
for a more aggressive adjuvant therapy. Finally, the issue 
whether determination of tissue expression of HE4 can pro-
vide prognostic benefit for the patients with uterine cervical 
neoplasms or it can be used for tumor screening should be 
investigated in larger series. 
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